ST6GAL1 and prostate carcinoma: Here, using VCaP and LNCaP cell line models, we show that prostate cancer cells with acquired resistance to enzalutamide have upregulated ST6GAL1 and significantly higher levels of α2-6 sialylated N-glycans.